DUBLIN--(BUSINESS WIRE)--The "Global Needle-free Drug Delivery Devices Market - Segmented by Technology, Application, and Geography - Growth, Trends, and Forecast (2018 - 2023)" report has been added to ResearchAndMarkets.com's offering.
The global needle-free drug delivery devices market is expected to register a CAGR of approximately 9.7% over the forecast period of 2018-2023. The market is primarily driven by the prevalence of chronic diseases and technological advancements in the field.
By region, owing to the presence of a large target population suffering from chronic diseases, improving healthcare infrastructure in several countries, and prospering economies attracting multinational biopharmaceutical companies to invest in India, China, and other South Asian countries, it is estimated that Asia-Pacific has a high-growth potential during the forecast period.
Key Highlights
- Inclination Toward Self-administration of Drugs
- Limitations Associated with Micro-needle Patches
- Asia-Pacific Offers Significant Opportunities
Notable Developments in the Market
- Antares Pharma Inc. received USD 4.75 million from Ferring Pharmaceuticals, for the sale of Antares' worldwide rights for the Zomajet needle-free auto-injector device.
- Namaste Technologies signed a definitive agreement with Inolife R&D Inc., wherein Namaste is granted exclusive rights for needle-free technologies, for applications of medical cannabis.
Key Topics Covered
1. Introduction
2. Research Methodology
3. Executive Summary
4. Key Inferences
5. Market Overview
6. Drivers, Restraints, Opportunities, and Challenges Analysis (DROC)
7. Market Segmentation
8. Competitive Landscape
9. Key Players
- 3M
- Akra Dermojet
- Antares Pharma
- D'Antonio Consultants International Inc.
- Endo Pharmaceuticals Inc.
- Penjet Corporation
- PharmaJet
- Valeritas Inc.
- Zogenix Inc.
10. Future of the Market
For more information about this report visit https://www.researchandmarkets.com/research/qxvq5m/global?w=4
